Elizabeth Mily
Known title: DirectorCIK: 0001808438
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Bristol Myers Squibb sees mixed trial results and dividend focus. Recent articles note BMY's 4.2% dividend yield and the trade‑off investors face between income and growth. Analysts also point to momentum in the stock rally but question whether new drugs can sustain further upside, especially after mixed Phase 3 results for its pulmonary fibrosis treatment. A shift in the company's portfolio toward newer products is also highlighted, adding context to the current market view.
Transaction History
| SOLV | ▲ Buy | Option Exercise | 3,403 | $0 | 4/30/2026 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 1,980 | $0 | 3/27/2026 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 3,564 | $0 | 5/13/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 3,662 | $0 | 4/1/2023 | View on chart |
| BMY | ▼ Sell | Other | 1,190 | $0 | 4/1/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,059 | $143K | 4/1/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 2,684 | $0 | 4/1/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 1,139 | $79K | 4/1/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 4,005 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 657 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 1,978 | $130K | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 3,658 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 118 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 1,602 | $105K | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 21,973 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 2,683 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 10,460 | $687K | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 3,662 | $0 | 4/1/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,194 | $162K | 4/1/2022 | View on chart |
| BMY | ▲ Buy | Option Exercise | 2,685 | $0 | 4/1/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 1,139 | $84K | 4/1/2022 | View on chart |
| BMY | ▼ Sell | Other | 1,508 | $0 | 4/1/2022 | View on chart |
| BMY | ▲ Buy | Option Exercise | 4,005 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 1,875 | $128K | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Other | 449 | $0 | 3/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Solventum Featured in Yahoo’s Overrated and Profitable Stock Lists
Yahoo highlighted Solventum in two recent articles. In one piece it was listed among stocks that may be overvalued, while the other article named it a profitable long‑term option. The coverage may influence how investors view the company’s valuation and growth prospects. The stock remains near the middle of its 52‑week range.
Solventum Featured in Yahoo’s Overrated and Profitable Stock Lists. Yahoo highlighted Solventum in two recent articles. In one piece it was listed among stocks that may be overvalued, while the other article named it a profitable long‑term option. The coverage may influence how investors view the company’s valuation and growth prospects. The stock remains near the middle of its 52‑week range.